CEO of DNA Sequencer Company Illumina Resigns Amid Pressure Over $7.1B Acquisition

Illumina's CEO Francis deSouza has stepped down from his role.
The resignation comes after activist investor Carl Icahn campaigned against deSouza over Illumina's purchase of cancer testing company Grail last year.
Illumina's senior vice president Charles Dadswell will serve as interim CEO while the board searches for a new CEO.
DeSouza will stay on in an advisory role until the end of July.
Illumina is appealing an FTC order demanding it unwind the Grail acquisition over antitrust concerns.